Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-01-2023 | Hepatic Encephalopathy | Case report

Atezolizumab/bevacizumab

Various toxicities: 7 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Chuma M, et al. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatology Research 52: 269-280, No. 3, Mar 2022. Available from: URL: http://doi.org/10.1111/hepr.13732 Chuma M, et al. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatology Research 52: 269-280, No. 3, Mar 2022. Available from: URL: http://​doi.​org/​10.​1111/​hepr.​13732
Metadata
Title
Atezolizumab/bevacizumab
Various toxicities: 7 case reports
Publication date
01-01-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-31503-0

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Pseudoephedrine

Case report

Chlorpromazine

Case report

Multiple drugs

Case report

Colchicine

Case report

Empagliflozin